#PAGE_PARAMS# #ADS_HEAD_SCRIPTS# #MICRODATA#

Comparison of Remifentanil and Sufentanil in Anaesthesia of Patients Operated on for Intracranial Disease


Authors: M. Lopourová;  J. Málek;  P. Mizner;  J. Pachl
Published in: Anest. intenziv. Med., , 2001, č. 4, s. 167-170
Category:

Overview

The aim of the study was to compare currently used perioperative analgesia with sufentanil to new opioid remifentanil in a set of neurosurgicalpatients operated on due to intracranial lesion. In a prospective open clinical study we randomized 20 patients in two groups. Ten patients in groupS received sufentanil perioperatively (initial rate 0.5 mcg/kg/hr), ten patients in group R received remifentanil (initial rate 0.1 mcg/kg/hr). The doseswere adjusted as requested by the patient. Anaesthesiologic management was equal and standard in both groups. We monitored hemodynamic changesperioperatively and postoperatively, time to extubation and adverse effects. We found statistically significant differences (S vs. R) only in time fromcompletion of surgery to extubation (24.2 ± 6.5 min vs 12.2 ± 2.7 min, p < 0.001), in the occurrence of postoperative pain (0 vs. 5, p < 0.05) andpostoperative tachycardia (0 vs. 6, p < 0.01). We observed a trend to more frequent occurrence of postoperative nausea and vomiting in R (0 vs. 4,p = 0.09). The average cost of analgesia was 176 CZK in s vs. 528 CZK in R (p < 0.001). In conclusion, we found that perioperative use of remifentanilduring intracranial operation does not possess a significant advantage over sufentanil.

Key words:
neuroanaesthesia - remifentanil - sufentanil

Full text is not available online.
If interested in a scan of this journal, contact NTO ČLS JEP.

Labels
Anaesthesiology, Resuscitation and Inten Intensive Care Medicine

Article was published in

Anaesthesiology and Intensive Care Medicine


2001 Issue 4

Most read in this issue
Login
Forgotten password

Enter the email address that you registered with. We will send you instructions on how to set a new password.

Login

Don‘t have an account?  Create new account

#ADS_BOTTOM_SCRIPTS#